Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

← catalyst calendar

NCT05908084 · readout ≤ 315 d

Sponsored by Humacyte, Inc. (industry) · HUMA — their whole pipeline →. With IQVIA Biotech.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
121actual
Sites
32
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-09-07actualWhen the study began enrolling
Primary completionJun 2027estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionJun 2028estimatedThe whole study's end, after follow-up
First posted2023-06-18actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-06-26actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • End Stage Renal Disease (ESRD)

Interventions

  • Biological: Acellular Tissue Engineered Vessel (ATEV) — also filed as Human Acellular Vessel (HAV)
  • Other: AVF

Primary outcomes

what the primary-completion date above is the date OF
The number of catheter-free days since randomization to Month 12.
measured 12 months
The rate of infections related to any HD access.
measured 12 months

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · HUMA's whole pipeline · Catalyst calendar · Every registered study · What changed